RSRobert C. Sergott

Robert C. Sergott

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert C. Sergott has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Green vessel signal on multicolor imaging as an early sign of ischemic vasculitis in IRVAN Syndrome: A case report

    by Daniel M. Markowitz, Jirat Nimworaphan, Carl D. Regillo, James P. Dunn, Robert C. Sergott

  • Open Access

    Fluorescence lifetime imaging ophthalmoscopy adds the retina to cortical pathology for visual dysfunction in neurodegenerative diseases

    by Jirat Nimworaphan, Daniel M. Markowitz, Robert C. Sergott

    Because neurodegenerative diseases such as Parkinson’s and Alzheimer’s Diseases [AD and PD] as well as the progressive forms of multiple sclerosis [MS] are invariably associated with clinically significant cortical symptoms such as language difficulties, motor skill deficits and cognitive impairments, especially memory, a tacit assumption evolved that visual disorders related to cortical dysfunction must localize only to the temporal, parietal and occipital lobes. Based upon our current understanding, retinal changes in MS are most likely secondary to optic neuropathy, whereas in AD and PD, they appear to represent primary retinal changes. The paradigm was reinforced by the lack of retinal findings using ophthalmoscopy. Spectral domain optical coherence tomography [OCT], optical coherence angiography [OCT-A], and fundus autofluorescence [FAF] have challenged this creed by uncovering structural changes within the retina over and above what can occur as a consequence of optic neuropathy in the case of MS. Still, definitive diagnostic and prognostic data have yet to emerge. Fluorescence lifetime imaging ophthalmoscopy [FLIO], a non-invasive, non-contact, painless imaging technology, measures nanosecond lifetimes of endogenous retinal fluorophores, some of which are linked to mitochondrial activity. Therefore, FLIO is a metabolic, not a structural imaging modality. Because mitochondrial dysfunction occurs in many neurodegenerative diseases, FLIO offers a unique strategy for investigating retinal metabolism in AD, PD, and MS. This article reviews the basic biomedical engineering of FLIO and reports preliminary data from these diseases, correlated with disease duration. These functional in vivo data are consistent with retinal metabolic changes in AD, PD, and progressive MS that were “hiding in plain sight” from structural examinations.


  • Open Access

    Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy

    by Robert C. Sergott, Valerio Carelli, Nancy J. Newman, Valérie Biousse, Patrick Yu-Wai-Man, Catherine Vignal-Clermont, Constant Josse, Magali Taiel, José-Alain Sahel, Piero Barboni, et al.

    This exploratory analysis aimed to identify predictive factors of final best-corrected visual acuity (BCVA) in patients with Leber hereditary optic neuropathy (LHON) harboring the m.11778G>A mutation who received lenadogene nolparvovec gene therapy. The following covariates were individually evaluated as possible factors associated with improved final BCVA: age, gender, timing of treatment, baseline BCVA value, and baseline optical coherence tomography (OCT) parameters. Univariate analyses were performed from three phase 3 studies (RESCUE, REVERSE, and REFLECT), using BCVA at 1.5 years post-treatment as the dependent variable. In 113 eyes treated at least 6 months after disease onset, the covariates statistically significantly associated with an improvement in final BCVA after having reached a nadir were thicker OCT measurements at baseline-specifically, outer segments of the macular ganglion cell layer (GCL) (superior, temporal, inferior, and nasal) and retinal nerve fiber layer (RNFL) quadrants (superior, inferior, and nasal) (P < 0.05). The largest effects were observed in the thickness of the superior outer GCL segments at baseline (-0.28 logMAR; 95% confidence interval [CI], -0.41 to -0.16) and temporal outer GCL segments at baseline (-0.26 logMAR; 95% CI, -0.38 to -0.13; both P <0.001). A better baseline BCVA in the dynamic phase of the disease was associated with a better final BCVA (-0.09 logMAR; 95% CI, -0.11 to -0.08; P < 0.0001). Better baseline BCVA values and baseline thicker GCL and RNFL at OCT measurements are key predictive factors of the improved BCVA 1.5 years after treatment in patients with MT-ND4 LHON who received lenadogene nolparvovec at least 6 months after disease onset.


  • Open Access

    Retinal mitochondrial Fluorescence‐Lifetime Ophthalmoscopy data in patients with Alzheimer’s Disease

    by Kylee Shivok, Elizabeth Affel, Robert C. Sergott

    Background: FLIO a novel in vivo reproducible, non‐invasive imaging technology, measures fluorescence lifetime decay in two spectral channels for short‐lived retinal chromophores in two domains: Channel 1 emission wavelength 498‐560 nm corresponding to NADH and FAD/ATP function and Channel 2, 560‐720 nm wavelength corresponding to lipofuscin/lysosomal function. These data reflect the retinal mitochondrial molecular environment. Mitochondrial dysfunction has been recently explored as a cause of decreased synaptic function and cognitive decline in AD. Only very limited data with first generation FLIO technology were previously reported.Method: Twenty‐two individuals [48 eyes], 11 AD patients and 11 controls, underwent FLIO with second generation FLIO manufactured by Heidelberg Engineering. Imaging data were analyzed using SPCImage technology.Result: Patients with AD demonstrated a right shift towards longer wavelength chromophores for both channels 1 and 2. The mean fluorescence decay time of the eye was also extended, leading to much broader wavelength plateaus compared to relative small areas under normal parabolic curve found in controls. In this small cohort, no differences were observed between amnestic and non‐amnestic patients with AD. Mitochondrial changes were more pronounced with longer disease duration and severity.Conclusion: FLIO detected changes consistent with changes in the retinal mitochondrial molecular environment for both NADH, FAD, and lipofuscin not otherwise visible with other retinal imaging techniques. FLIO data add support to the hypothesis that mitochondrial dysfunction may contribute to AD neurodegeneration. FLIO may help to resolve the question of whether mitochondrial dysfunction is a primary event for AD and/or a secondary amplifier of the disease. Because it is non‐invasive, painless, reproducible, FLIO has promise as an imaging biomarker to aid in the diagnosis of AD as well as an outcome metric for longitudinal clinical trials.


  • Open Access

    Gene Therapies for the Treatment of Leber Hereditary Optic Neuropathy

    by José-Alain Sahel, Nancy J. Newman, Patrick Yu-Wai-Man, Catherine Vignal-Clermont, Valerio Carelli, Valérie Biousse, Mark L. Moster, Robert Sergott, Thomas Klopstock, Alfredo A. Sadun, et al.


  • Open Access

    Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies

    by Mark L. Moster, Robert C. Sergott, Nancy J. Newman, Patrick Yu-Wai-Man, Valerio Carelli, Molly Scannell Bryan, Gerard Smits, Valérie Biousse, Catherine Vignal-Clermont, Thomas Klopstock, et al.

    Objective: This report presents a cross-sectional analysis of the baseline characteristics of subjects with Leber hereditary optic neuropathy enrolled in the gene therapy trials RESCUE and REVERSE, to illustrate the evolution of visual parameters over the first year after vision loss. Methods: RESCUE and REVERSE were 2 phase III clinical trials designed to assess the efficacy of rAAV2/2-ND4 gene therapy in ND4-LHON subjects. At enrollment, subjects had vision loss for ≤6 months in RESCUE, and between 6 and 12 months in REVERSE. Functional visual parameters (best-corrected visual acuity [BCVA], contrast sensitivity [CS], and Humphrey Visual Field [HVF]) and structural parameters assessed by spectral-domain optical coherence tomography were analyzed in both cohorts before treatment. The cross-sectional analysis of functional and anatomic parameters included the baseline values collected in all eyes at 2 different visits (Screening and Inclusion). Results: Seventy-six subjects were included in total, 39 in RESCUE and 37 in REVERSE. Mean BCVA was significantly worse in RESCUE subjects compared with REVERSE subjects (1.29 and 1.61 LogMAR respectively, P = 0.0029). Similarly, mean CS and HVF were significantly more impaired in REVERSE vs RESCUE subjects (P < 0.005). The cross-sectional analysis showed that the monthly decrease in BCVA, ganglion cell layer macular volume, and retinal nerve fiber layer thickness was much more pronounced in the first 6 months after onset (+0.24 LogMAR, −0.06 mm3, and −6.00 μm respectively) than between 6 and 12 months after onset (+0.02 LogMAR, −0.01 mm3, and −0.43 μm respectively). Conclusion: LHON progresses rapidly in the first months following onset during the subacute phase, followed by relative stabilization during the dynamic phase.


  • Top Cited Papers

    Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy

    by Patrick Yu-Wai-Man, Nancy J. Newman, Valerio Carelli, Mark L. Moster, Valerie Biousse, Alfredo A. Sadun, Thomas Klopstock, Catherine Vignal-Clermont, Robert C. Sergott, Günther Rudolph, et al.

    At 96 weeks after unilateral intravitreal injection of rAAV2/2- ND4 , vision improved in both eyes in 78% of subjects affected with LHON.


  • Open Access

    Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study

    by Valérie Biousse, Nancy J. Newman, Patrick Yu-Wai-Man, Valerio Carelli, Mark L. Moster, Catherine Vignal-Clermont, Thomas Klopstock, Alfredo A. Sadun, Robert C. Sergott, Rabih Hage, et al.

    Background: RESCUE and REVERSE were 2 Phase 3 clinical trials that assessed the efficacy and safety of intravitreal gene therapy with lenadogene nolparvovec (rAAV2/2-ND4) for the treatment of Leber hereditary optic neuropathy (LHON). RESTORE is the long-term follow-up study of subjects treated in the RESCUE and REVERSE trials. Methods: In RESCUE and REVERSE, 76 subjects with LHON because of the m.11778 G>A mutation in the mitochondrial gene ND4 received a single unilateral intravitreal injection of lenadogene nolparvovec. After 96 weeks, 61 subjects were enrolled in the long-term follow-up study RESTORE. The best-corrected visual acuity (BCVA) was assessed over a period of up to 52 months after onset of vision loss. A locally estimated scatterplot smoothing regression model was used to analyze changes in BCVA over time. Vision-related quality of life was reported using the visual function questionnaire-25 (VFQ-25). Results: The population of MT-ND4 subjects enrolled in RESTORE was representative of the combined cohorts of RESCUE and REVERSE for mean age (35.1 years) and gender distribution (79% males). There was a progressive and sustained improvement of BCVA up to 52 months after the onset of vision loss. The final mean BCVA was 1.26 logarithm of the minimal angle of resolution 48 months after the onset of vision loss. The mean VFQ-25 composite score increased by 7 points compared with baseline. Conclusion: The treatment effect of lenadogene nolparvovec on BCVA and vision-related quality of life observed 96 weeks (2 years) after treatment in RESCUE and REVERSE was sustained at 3 years in RESTORE, with a maximum follow-up of 52 months (4.3 years) after the onset of vision loss.